Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alvotech ( (ALVO) ) just unveiled an update.
On January 29, 2026, Alvotech reported that it had entered into a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining global patent disputes over its biosimilar to Eylea 2mg (aflibercept 40 mg/mL), which is already approved for marketing in the European Economic Area, the United Kingdom and Japan. Together with a previously disclosed deal granting a late‑2026 U.S. license entry date, the settlement gives Alvotech worldwide rights to manufacture and supply its aflibercept biosimilar to commercial partners, and sets staggered launch dates: as of January 1, 2026 in the UK and Canada, May 1, 2026 in the European Economic Area and most other non‑U.S. markets, and November 1, 2026 in Japan for all approved indications, a move that positions the company and its regional partners to accelerate global rollout of a key ophthalmology biosimilar and potentially increase competitive pressure in retinal disease treatments.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotechnology company focused exclusively on developing and manufacturing biosimilar medicines, aiming to offer high-quality, cost-effective alternatives to branded biologics. Founded by Robert Wessman, the company operates with a fully integrated model and has a pipeline of eight disclosed biosimilar candidates targeting autoimmune diseases, eye disorders, osteoporosis, respiratory disease and cancer, supported by a network of commercial partners across the U.S., Europe, Japan, China, other Asian markets, and much of South America, Africa and the Middle East.
Average Trading Volume: 602,064
Technical Sentiment Signal: Sell
Current Market Cap: $1.59B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.